Health Catalyst (HCAT) announced it has repurchased shares of its common stock in an aggregate amount of approximately $5M. These repurchased shares were acquired between March 3 and March 10, as part of Health Catalyst’s existing share repurchase program approved by its board of directors on August 2, 2022, which authorized repurchases of up to $40M of common stock. These recent repurchases resulted in the retirement of approximately 1.1M shares of common stock.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $5 from $7 at Stephens
- Health Catalyst’s Earnings Call Highlights Robust Growth and Strategic Challenges
- Health Catalyst announces multiyear agreement with Signature Health
- Health Catalyst price target lowered to $10 from $13 at BTIG
- Health Catalyst’s Promising Financial Trajectory and Growth Potential Justifies Buy Rating